Electra Therapeutics (NASDAQ:ETRA) Upgraded to "Hold" at Zacks Research

Key Points

• Zacks Research upgraded Electra Therapeutics to a “Hold” rating, while the broader analyst consensus remains “Buy” with an average price target of $34.00.
• Recent coverage was generally positive: Jefferies set a $32 price target, Evercore issued an “Outperform” rating with a $36 target, and TD Cowen and Cantor Fitzgerald also rated the stock positively.
• ETRA opened at $8.75, down 2.1%, near its 52-week low of $8.50. Directors Orbimed Advisors and Carl L. Gordon each purchased 1.33 million shares at $15 per share, worth about $20 million.

Electra Therapeutics (NASDAQ:ETRA - Get Free Report) was upgraded by research analysts at Zacks Research to a "hold" rating in a note issued to investors on Wednesday, Zacks reports.

Other analysts have also issued research reports about the company. Jefferies Financial Group assumed coverage on Electra Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $32.00 price target for the company. TD Cowen started coverage on shares of Electra Therapeutics in a research report on Tuesday. They set a "buy" rating on the stock. Wall Street Zen raised shares of Electra Therapeutics to a "hold" rating in a research report on Saturday, September 26th. Evercore assumed coverage on shares of Electra Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Electra Therapeutics in a research report on Tuesday. They issued an "overweight" rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $34.00.

Electra Therapeutics Trading Down 2.1%

ETRA opened at $8.75 on Wednesday. Electra Therapeutics has a 52-week low of $8.50 and a 52-week high of $15.50.

Insider Activity at Electra Therapeutics

In other news, Director Orbimed Advisors Llc bought 1,333,333 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was purchased at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director owned 5,126,891 shares of the company's stock, valued at approximately $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon bought 1,333,333 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their position. The SEC filing for this purchase provides additional information.

About Electra Therapeutics

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company's research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body's ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.